MMP-9 Expression in Permanent Mature Teeth With Symptomatic Pulpitis

Pulpitis Clinical Trial

Official title:

A Prospective Clinical Pilot Study of MMP-9 Expression and Short-term Outcome of Coronal Pulpotomy in Mature Permanent Teeth With Symptomatic Pulpitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03807674
• Other study ID #: BEC-LSMU(R)-01
• Status: Completed
• Phase: N/A
• Start date: March 27, 2017
• Est. completion date: February 11, 2018

Study information

• Verified date: January 2019
• Source: Lithuanian University of Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Matrix metallopeptidase-9 (MMP-9) expression was compared in healthy and inflamed pulp and the outcome of coronal pulpotomy in teeth with symptomatic pulpitis was assessed. After procedure blood samples were examined using Elisa kit.

Description:

Introduction: Widely used diagnostic tests do not provide information to distinguish the pulp inflammation stage while improvement of materials, techniques and vital pulp therapy have received a wider acceptance in symptomatic pulpitis treatment. The aim of this clinical study was to compare MMP-9 expression in healthy and inflamed pulp and to assess the short-term outcome of coronal pulpotomy in mature permanent teeth with symptomatic pulpitis.

Methods: Patients diagnosed with symptomatic pulpitis were included in this clinical study. Coronal pulpotomy was performed using calcium-silicate based material and blood samples were taken. Initial and postoperative pain was recorded by Heft-Parker visual analog scale at 24 hours and 72 hours after the procedure. In control group teeth with healthy pulp were used. During follow-up visits after three and six-months, patients were examined clinically and radiographically. The ELISA kit was used to determine the levels of MMP-9 in inflamed and healthy coronal pulp tissue.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: February 11, 2018
• Est. primary completion date: July 15, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 14 Years to 33 Years

Eligibility

Inclusion Criteria:

• Teeth diagnosed with symptomatic pulpitis

• Patients who did not use any NSAIDs before the treatment

• Positive cold test of investigated teeth

• Clinically dental caries in contact with pulp chamber

• Permanent teeth with radiographically closed root apex

Exclusion Criteria:

• Patients who refuse to participate in the study

• Medically compromised patients (with immunosuppressive/systemic diseases, patients on medications)

• Teeth with periapical radiolucency or clinical signs of apical periodontitis

• Periodontological compromised teeth (probing depth =4mm)

• Internal/external root resorption in periapical radiograph

• Pulp chamber and/or root canal calcification in periapical radiograph

• Teeth with unrestorable crown

• Teeth with a negative response to cold test

Related Conditions & MeSH terms

• Pulpitis

Intervention

Procedure:
• Coronal pulpotomy
Coronal pulpotomy was performed with a sterile high-speed round bur under water coolant. Pulp vitality was confirmed by the presence of bleeding pulp tissue from all of the canal orifices. Hemostasis was achieved through the application of a pellet moistened with 2.5% NaOCl for two minutes and was repeated as needed. Calcium-silicate based material was prepared ac-cording to the manufacturer's instructions and gently placed over the pulp to fill the entire cavity.

Locations

Country	Name	City	State
Lithuania	Lithuanian University of Health Science	Kaunas

Sponsors (1)

Lead Sponsor	Collaborator
Egle Gvazdaityte

Country where clinical trial is conducted

Lithuania, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MMP-9 amount measurement using ELISA kit	The MMP-9 amount in the pulp blood samples was measured using the MMP-9 Human ELISA Kit. The measurement procedure was followed according to the manufacturer's instructions. The anti-MMP-9 polyclonal antibody was pre-coated on 96-well plates. Blood samples and a biotin-conjugated antibody were added to the wells supplemented with Avidin-Biotin-Peroxidase Complex and 3,3',5,5'-tetramethylbenzidine in a mildly acidic buffer. A blue-colored product was produced and turned to yellow after an acidic stop solution was added. The intensity of the color yellow was proportional to the MMP-9 amount bound on the plate. The optical density absorbance was measured spectrophotometrically at 450nm in a microplate reader and the concentration of MMP-9 was calculated. For the expression of MMP-9 concentrations in the samples, a standard curve was used.	All samples were measured in one time (during 12 hours)